Ergoteles LLC Glycomimetics Inc Transaction History
Ergoteles LLC
- $68.2 Billion
- Q3 2023
Shares
2 transactions
Others Institutions Holding GLYC
# of Institutions
42Shares Held
25.6MCall Options Held
1.94MPut Options Held
153K-
Bvf Inc San Francisco, CA9.54MShares$1.62 Million0.08% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$1.46 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.7MShares$458,4740.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny827KShares$140,5640.0% of portfolio
-
Goldman Sachs Group Inc New York, NY804KShares$136,7380.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $8.91M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...